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Abstract
Medulloblastoma is a primary brain tumor found in the
cerebellum of children. The tumor occurs in associa-
tion with two inherited cancer syndromes: Turcot
syndrome and Gorlin syndrome. Insights into the
molecular biology of the tumor have come from
looking at alterations in the genes altered in these
syndromes, PTC and APC, respectively. Murine mod-
els of medulloblastoma have been constructed based
on these alterations. Additional murine models that,
while mimicking the appearance of the human tumor,
seem unrelated to the human tumor’s molecular
alterations have been made. In this review, the clinical
picture, origin, molecular biology, and murine models
of medulloblastoma are discussed. Although a great
deal has been discovered about this tumor, the genetic
alterations responsible for tumor development in a
majority of patients have yet to be described.
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Introduction
Medulloblastoma is a primary brain tumor that occurs in the
cerebellum of children and young adults. The nomencla-
ture for this tumor is somewhat controversial. The name
‘‘medulloblastoma’’ was given by Bailey and Cushing [1]
in 1925; they suggested that these tumors arise from a
hypothesized central nervous system (CNS) precursor cell
called a medulloblast. Such a cell has never been identi-
fied, leading Rorke [2] to include medulloblastoma in a
group of histologically similar CNS tumors, which she
called primitive neuroectodermal tumors (PNETs). Some
of the controversies regarding nomenclature have been
addressed by recent studies of gene expression using
array analysis (see below). Because these tumors arise
in the cerebellum, patients present with symptoms of
cerebellar dysfunction, including balance problems and
incoordination. In addition, because the tumor frequently
fills the fourth ventricle and blocks the normal circulation of
cerebrospinal fluid (CSF), patients often present with
symptoms and signs of hydrocephalus, including head-
ache, vomiting, diplopia, and papilledema. Medulloblasto-
mas are best demonstrated by magnetic resonance
imaging (MRI), although characteristic findings can also
be seen on computed tomography (Figure 1). Because
these tumors have a propensity to spread through the CSF to
distant CNS sites, patients should have MRI of the entire brain
and spine. Medulloblastoma has an incidence of two to five
cases per 10,000 population per year, resulting in about 240
new cases per year in the United States [3]. Most medulloblas-
tomas arise sporadically, although medulloblastoma may arise
rarely as part of an inherited cancer syndrome (see below).
Grossly, medulloblastomas most often arise in the roof of
the fourth ventricle. They grow to invade the cerebellar vermis
and fill the ventricle, often invading through the ependyma in
the floor of the ventricle to enter the brainstem (Figure 1). Less
commonly, the tumor arises in the cerebellar hemisphere.
Grossly, the tumors appear to be relatively well circumscribed.
The tumor may contain areas of calcification or necrosis.
Microscopically, the tumor cells are small with little cytoplasm
(Figure 2A). They occur in sheets and may show signs of
neuronal or glial differentiation. Histologic subtypes of medul-
loblastoma have been described and include the desmoplastic
variant and the large cell variant. The desmoplastic variant is
composed of islands of larger, pale cells in a sea of smaller,
more typical medulloblastoma cells. In addition, an abundant
collagenous matrix is present. In the large cell variety, the cells
are larger and more pleomorphic. Microscopically, the tumor is
invasive at its edges, although penetration into the surrounding
cerebellum is somewhat limited. Immunhistochemical staining
is frequently positive for synaptophysin and NeuN, indicating
that neuronal differentiation and may be regionally positive for
glial fibrillary acid protein (GFAP), indicating astrocytic differ-
entiation in some parts of the tumor.
Current Therapy of Medulloblastoma
Currently, patients with medulloblastoma are best treated with
surgical removal of the tumor, and adjuvant radiation therapy
and chemotherapy (for review, see Refs. [4–7]). Many pro-
spective, randomized trials have demonstrated that patients do
better if most—if not all—of the tumor is removed. Radiation
therapy, at a dose of at least 55 Gy to the tumor, has also been
shown to prolong survival and result in cures. Because the
tumor has a propensity to spread in the CSF, an additional
35 Gy is given to the entire brain and spinal cord. The
devastating effects on intellect caused by the radiation
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therapy in young children have been well documented. The
younger is the child at the time of irradiation, the worse is
the intellectual outcome. For this reason, children under the
age of 3 years are often treated with chemotherapy alone.
Agents with demonstrated efficacy against medulloblastoma
include DNA alkylating agents such as ethylnitrosoureas
(BCNU and CCNU) and the platinum derivatives (cis-plati-
num and carbo-platinum). Chemotherapy is also used in
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Figure 1. MRI of medulloblastoma. This T1-weighted, gadolinium diethylenetriamine pentaacetic acid (DTPA)–enhanced MR scan of a patient with a
medulloblastoma demonstrates a mass (large area of white) in the cerebellum, which fills the fourth ventricle and displaces it anteriorly.
Figure 2. (A) Photomicrograph of a human desmoplastic medulloblastoma, demonstrated as small, tightly packed cells with little cytoplasm. A pale island is seen in
the center of the image as an area of less tightly packed cells. Hematoxylin and eosin staining, 400. (B) Photomicrograph of murine tumor of the cerebellum from
a Ptc+/ mouse. Note the similarity to the human tumor. Hematoxylin and eosin staining, 400. (Image courtesy of Dr. Cynthia Wetmore, Rochester, MN.)
conjunction with radiation therapy in older patients, especial-
ly those with CSF metastases at presentation.
Cerebellar Development
The cerebellum develops from neuronal precursors located
in the rhombic lip of the fetal brain (for review, see Ref. [8]).
These precursors migrate tangentially to form the external
granular cell layer (EGL) of the developing cerebellum.
Purkinje neurons and Bergman glia arise from precursors
in the subventricular zone andmigrate toward the EGL. In the
EGL, the granular cell precursors continue to proliferate in
the outer zone. Postmitotic neuronsmove to the inner zone of
the layer and then migrate along Bergmann glial fibers to
finally reside in the internal granular cell layer (IGL). The EGL
eventually disappears as all cell division ceases and all
postmitotic neurons move to the IGL. The number of neurons
that finally reside in the IGL is large. In fact, there are more
neurons in the IGL than in the rest of the brain combined.
The sonic hedgehog (SHH) signaling pathway plays an
essential role in cerebellar development [9,10]. The receptor
for SHH, patched (PTC), is a membrane-associated protein
containing 12 transmembrane domains [11,12]. Associated
with PTC in the membrane is the effector molecule, smooth-
ened (smo) [13]. PTC appears to function to inhibit signaling
by smo. Binding of SHH to PTC releases this inhibition,
resulting in activation of the intracellular components of the
pathway. The main effector of SHH in the cell may be gli1,
a transcriptional activator [14] (Figure 3). In the developing
cerebellum, PTC is expressed by neuronal precursors in the
EGL [9,10]. SHH is produced by Purkinje neurons that lie
beneath the EGL. In vitro, SHH has been shown to be a
potent mitogen for EGL precursors. Blocking of SHH signal-
ing in vivo leads to hypoplastic cerebella in which granule
neurons are greatly reduced or absent. These results strong-
ly suggest that EGL neuronal precursors are stimulated to
divide by SHH signaling. The factors that lead to differenti-
ation andmigration of the postmitotic neurons are not clear at
this time, although b-FGF has been shown to block the SHH-
induced proliferation of EGL cells in vitro. Figure 4 summa-
rizes role of the SHH pathway in the development of the
cerebellum.
Other signaling pathways have been implicated in the
development of the cerebellum. Both neurotrophins and their
receptors have been found to be expressed in the developing
cerebellum. The temporal pattern of expression suggests
that brain-derived neurotrophic factor (BDNF) and its recep-
tor, trkB, may be involved in the division of cells in the EGL,
and that NT3 and its receptor, trkC, may be involved in the
terminal differentiation of these cells into internal granular
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Figure 3. The SHH/PTC pathway. By binding to the membrane-bound PTC receptor, SHH removes the inhibition of v-smo mediated by PTC. This ultimately results
in increased gli-mediated transcription. Su-fu and PKA are downstream inhibitors of this process.
layer neurons [15,16]. This model is of interest in light of data
suggesting that the expression of trkC in medulloblastoma is
a marker for better prognosis [17,18].
Medulloblastoma: Cell of Origin
Medulloblastomas are observed to differentiate along glial
and neuronal pathways in situ, suggesting that these tumors
are derived from primitive, pluripotent, neuroepithelial stem
cells. This conclusion is supported by studies of PNET cell
lines that demonstrate expression of specific, developmen-
tally regulated proteins in PNETs [19]. Medulloblastomas
have been demonstrated to express zic, a gene normally
expressed only in the EGL of the developing cerebellum
and its derivatives, suggesting that medulloblastoma arises
from EGL precursor cells [20,21]. Given the rapid prolif-
erative capacity of EGL precursors and the pattern of
gene expression seen, EGL cells and their derivatives seem,
by far, the most likely origin of medulloblastoma. Other
cerebellar cells, such as Purkinje cells, basket neurons, or
glial cells, are unlikely to be cells of origin for medulloblas-
toma. Evidence that other stem cells in the cerebellum may
give rise to medulloblastoma comes from murine models of
human medulloblastoma (see below). For example, a model
of medulloblastoma has been generated using the GFAP
promoter to drive expression of the RecA recombinase,
resulting in tissue-specific inactivation of RB1 [22]. In this
work, cells expressing GFAP were identified in the develop-
ing cerebellum, although the vast majority of EGL precursors
did not express GFAP.
Medulloblastoma: Karyotypic Abnormalities
Only one karyotypic abnormality has been found to be typical
of medulloblastoma—the presence of an isochromosome
17q, present in about 50% of tumors [23]. The breakpoint
has been localized to 17p11.2, but no tumor-specific gene
rearrangement has been identified. Despite multiple studies,
no tumor-suppressor gene that can be implicated in the
development of medulloblastoma has been found on chro-
mosome 17p. Specifically, no alteration in p53 has been
identified with more than 100 tumors investigated to date.
The breakpoint for the rearrangement has been mapped
to 17p11.2 [24]. Other less common karyotypic abnormali-
ties, including loss of heterozygosity (LOH) on chromosome
9q, have been identified in about 20% of medulloblastomas.
Interestingly, the loss of 9q in medulloblastoma has been
correlated with the desmoplastic subtype [25].
Medulloblastoma: Molecular Genetics and Animal Models Raffel 313
Neoplasia . Vol. 6, No. 4, 2004
Figure 4. The role of SHH in cerebellar development. Granule neuronal precursors (A–D) migrate tangentially from the rhombic lip and may use the SHH pathway
in transient autocrine manner. Purkinje neurons and later-born Bergmann glia (B) derive from the ventricular zone and migrate toward the EGL. SHH from the
Purkinje neurons induces Bergmann glia maturation (C). In the later EGL, granule neuronal precursors proliferate in the outer zone, utilizing SHH secreted from
Purkinje neurons. At the same time, mature glia send their extensions toward the inner EGL (D) and these or other cortical cells may provide factors that promote
the differentiation if granule neurons, antagonizing the effects of SHH. Granule cells then migrate on glial fibers across the molecular and Purkinje layers to form the
IGL. Maintained autocrine SHH signaling in the EGL (E) may result in the development of cerebellar tumors. (Reprinted with permission from Ref. [3].)
Analyses of Gene Expression in Medulloblastoma
Two recent reports of gene expression in medulloblastoma
have added insights to the basic biology of these tumors. In
the first of these, medulloblastoma samples were divided into
two groups, depending upon whether CSF dissemination of
tumor was seen at the time the patient presented with the
tumor [26]. Gene expression was analyzed on Affymetrix
G110 cancer arrays, which are enriched for genes thought to
be important in cancer biology. Fifty-nine genes that had
increased expression in the metastatic tumors compared to
the nonmetastatic tumors were identified. An additional 29
genes were identified, which had decreased expression in
the metastatic tumors. Two of theses genes, PDGFRa and
SPARC, were shown by immuohistochemical staining to be
expressed differentially between metastatic and nonmeta-
static tumors. In addition, antibodies to PDGFRa blocked
tumor cell migration in in vitro assays. These investigators
were able to use the pattern of gene expression to predict
which tumors presented with CSF metastases in a blinded
group of tumors. These results suggest that there may be
genes important in the progression of medulloblastoma, or
that alterations in different pathways may be responsible for
the differences in prognosis seen between tumors present-
ing without and with CSF dissemination.
In the second study, a group of ‘‘embryonal tumors’’ of the
CNS, including medulloblastomas, extracerebellar PNETs,
atypical teratoid/rhabdoid tumors, and malignant gliomas,
was presented [27]. Gene expression was analyzed on
Affymetrix HuGene FL arrays, containing 5920 known genes
and 897 expressed sequence tags. The first finding from this
data set was that each tumor type could be easily distin-
guished from the others based on gene expression pattern.
Especially interesting was the ability to distinguish medullo-
blastomas from other CNS PNETs, suggesting that the
lumping of these tumors together, as proposed by Rorke,
may be inappropriate. The medulloblastomas often
expressed genes normally expressed in the EGL, lending
credence to the hypothesis that EGL precursors represent
the cell of origin of medulloblastoma. Second, these inves-
tigators were able to distinguish ‘‘classic’’ medulloblastomas
from desmoplastic medulloblastomas. The important genes
with increased expression in the desmoplastic tumors were
those involved in the SHH/PTC pathway (see below). Lastly,
using an eight-gene model, these investigators were able to
accurately predict outcome in their patients with medullo-
blastoma. Genes associated with favorable clinical outcome
included TRKC and other genes characteristic of cerebellar
differentiation. In contrast, these genes were underex-
pressed in tumors with poor prognosis and genes involved
in cell proliferation were overexpressed.
Congenital Cancer Syndromes and Medulloblastoma
Medulloblastomas may occur in association with two differ-
ent inherited cancer syndromes: Gorlin syndrome and Turcot
syndrome. Nevoid basal cell carcinoma syndrome (NBCCS),
also called Gorlin syndrome or basal cell nevus syndrome, is
an autosomal dominant disorder [28]. Affected individuals
develop multiple basal cell carcinomas, multiple odontogenic
keratocysts of the jaws, palmar and plantar dyskeratoses,
and skeletal anomalies, especially rib malformations. In
addition, at least 40 cases of medulloblastoma have been
reported in patients with this syndrome, indicating that about
3% of Gorlin patients develop this tumor [29,30]. The gene
for Gorlin syndrome has been mapped to chromosome
9q22.3 [31,32]. Two studies have reported loss of genetic
markers mapped to 9q in medulloblastoma. In the first study,
16 patients were examined with 12 microsatellite markers
mapping between 9q13 and 9q34 [33]. Two tumors (12.5%)
showed LOH with microsatellite markers in this region. In the
second study, medulloblastomas from 20 patients, 17 with
sporadic tumors and 3 with NBCCS, were investigated with
seven microsatellite markers mapped to 9q22.3 to 9q31 [34].
Both informative tumors from patients with NBCCS showed
LOH for markers in the region; the third patient was not
informative. Three of the 17 sporadic tumors also showed
LOH on 9q. Interestingly, all three of the tumors from patients
with NBCCS in this study were designated desmoplastic me-
dulloblastomas. The other three tumors with LOH on 9q were
among six desmoplastic tumors in the sporadic group. Thus,
all of the tumors with LOH on 9q in this study were desmo-
plastic, raising the possibility that an NBCCS gene mutation
is involved in the development of this subclass of tumor.
The gene at 9q22.3 responsible for NBCCS has been
identified as the PTCH gene, the human homolog of the
Drosophila patched gene [35,36]. The Drosophila gene
encodes a protein with 12 putative transmembrane domains;
it may function as a receptor or transporter [37,38]. The
protein has an essential role in correct patterning of larval
segments and imaginal discs during adult fruit fly develop-
ment; a similar role in humans may explain the congenital
anomalies associated with NBCCS.
PTCH mutations have been described in patients with
NBCCS and in spontaneous basal cell carcinomas. A large
number of such mutations have been reported, including
single base substitutions, insertions ranging from a single
base to 300 bases, and deletions ranging from a single base
to 37 bases [35,36,39–42]. The described mutations are
fairly evenly distributed throughout the PTCH gene; no
‘‘mutational hot spots’’ have been identified.
Turcot syndrome is a hereditary disorder in which affected
individuals have multiple colonic polyps and a brain tumor,
either glioblastoma multiforme or medulloblastoma [43]. In
one study, mutations in the APC gene were identified in
the group of patients with Turcot syndrome who developed
medulloblastoma [44]. The relative risk for developing a
medulloblastoma in patients with Turcot syndrome and
an APC gene mutation is 92 times that in the general
population.
APC functions as a key regulator in a complex develop-
mental pathway (Figure 5). In the cytoplasm, APC associ-
ates with at least seven proteins, including b-catenin,
glycogen synthase kinase 3b (GSK-3b), axin1 and axin2,
b-TrCP, the B6 subunit of the PP2A phosphatase, and hDLG
[45–55]. The control of the levels of free b-catenin in the
cytoplasm by APC defines the role of APC as a tumor
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suppressor. Normally, free levels of b-catenin are low, as
binding of b-catenin by APC sequesters b-catenin and tar-
gets the protein for degradation. APC only binds b-catenin
when b-catenin is hyperphosphorylated. b-Catenin is phos-
phorylated by GSK-3b, a serine/threonine kinase. b-Catenin
contains four phosphorylation sites for GSK-3b, three serines
and one threonine, all encoded in exon 3 of the b-catenin
gene. When APC is inactivated by mutation (e.g., in colon
carcinoma), levels of cytoplasmic b-catenin rise. Free
b-catenin associates with members of the Tcf family
[56–58]. Four family members have been described; all
are transcription-regulating proteins with DNA-binding
activity. When b-catenin associates with Tcf, the complex
moves to the nucleus and upregulates the expression of
genes that increase the rate of cell division, either by
stimulating cell proliferation or by inhibiting apoptosis.
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Figure 5. The wnt signaling pathway. Binding of wnt to its receptor, frizzled, leads ultimately to translation of -catenin and Tcf into the nucleus, resulting in
transcription of genes controlled by this transactivator. The large complex involved in regulating free cytoplasmic concentrations of -catenin contains axin1 and
axin2, APC, and GSK-3. Phosphorylation of -catenin by GSK-3 in the complex leads to degradation of -catenin by the ubiquitin system.
Genetic Alterations in Medulloblastoma
Based on the germline gene alterations found in the inherited
syndromes described above, sporadic medulloblastomas
have been investigated for alterations of the involved genes.
Inactivation of the PTCH locus by deletion and mutation
has been found in about 10% of sporadic medulloblastomas,
suggesting that PTCH functions as a classic tumor suppres-
sor in this subset of tumors [59–64]. An analysis of the
SHH/PTCH pathway reveals that other genes in the path-
way might be altered to give a phenotype similar to that
caused by PTC inactivation. An investigation looking for
these alterations in 15 other pathway genes has revealed
only very rare mutations in v-smo and suppressor of fused
[su(fu)] [60,65,66]. This finding suggests that there is some-
thing unique about PTCH inactivation, or that the PTCH
locus is relatively easy to inactivate through mutation or
deletion.
Similarly, the APC gene has been investigated for inac-
tivation in sporadic medulloblastoma. Surprisingly, in light of
the association between germline APC gene mutation and
medulloblastoma seen in Turcot syndrome, APC gene muta-
tions have rarely been identified in spontaneously occurring
medulloblastomas. In one study, 47 sporadic medulloblas-
tomas were examined for mutations in the APC mutation
cluster region, comprising 10% of the gene, where more than
two thirds of the mutations seen in colorectal carcinoma
occur [67]. No tumor had an APC mutation in this region.
However, the entire gene was not investigated in this report.
Interestingly, in the two medulloblastomas in this study that
were removed from patients with Turcot syndrome, the
germline mutation was identified in tumor DNA, but no
mutation was seen in the other APC allele. In a second
study, DNA from 23 medulloblastomas was examined for
deletions in the region of the APC gene [68]. No LOH was
found in this region in any tumor. However, the four micro-
satellite markers used in this study, although the closest to
APC available at the time, were at least 30 to 70 kilobases
from the APC locus. In a third study, two tumors among 46
medulloblastomas were found to have APC mutations [69].
However, the mutations identified were very conservative
(i.e., alanine to valine and valine to isoleucine). The muta-
tions did not occur in defined functional domains of the
protein. The functional consequences of these mutations
are not clear. Taken together, these results indicate that
APC mutations in sporadic medulloblastoma are quite rare
and may have no functional consequence.
Because b-catenin/Tcf complexes are translocated to the
nucleus, nuclear localization of b-catenin, demonstrated
immunohistochemically, has been used as a marker for
tumors with active b-catenin/Tcf transcription [70–73]. Nu-
clear localization of b-catenin occurs in tumors with inacti-
vated APC or with oncogenic b-catenin mutations,
suggesting that this finding identifies tumors with increased
b-catenin/Tcf transcription, regardless of the mechanism
responsible. Immunohistochemical staining for b-catenin
has been performed in medulloblastoma [74]. Nine of 51
sporadic medulloblastomas were found to have nuclear
localization of b-catenin. This result suggests that at least
20% of medulloblastomas have alteration in the control of
b-catenin levels other than APC inactivation.
In colon carcinoma, free b-catenin levels may be in-
creased by two mechanisms. The first, inactivation of APC,
has been described above. The second mechanism involves
mutation of the b-catenin gene (locus CTNNB1) itself [75].
Mutations of b-catenin that alter the GSK-3b phosphorylation
sites in exon 3 have been described. These missense
mutations change the serines or threonines that are
GSK-3b phosphorylation sites to cysteine, and prevent
b-catenin from being completely phosphorylated. Cotrans-
fection experiments using a reporter construct and mutated
b-catenin demonstrated that these mutations exerted
a dominant effect, rendering b-catenin/Tcf transcription
resistant to APC-mediated downregulation. Transcriptional
activities of b-catenin/Tcf reporter constructs in cells with
wild-type APC transfected with mutant b-catenin were at
least six times higher than in the same cells transfected with
wild-type b-catenin. Gel shift analysis also demonstrated that
free b-catenin was constitutively bound to Tcf-4 in nuclear
extracts from cells containing mutant b-catenin, even in the
presence of wild-type APC. Functionally similar mutations in
which exon 3 has been deleted from the b-catenin gene have
been described [76]. Taken together, these data indicate that
mutations eliminating a GSK-3b phosphorylation site from
b-catenin result in a protein that is no longer regulated by
APC, but that continues to function as a transactivator when
bound to Tcf. This model predicts that mutated b-catenin
functions as a dominant oncogene, and this has been shown
to be the case. As predicted by this model, inactivating
mutations of APC and oncogenic mutations in b-catenin
occur in nonoverlapping subsets of colon carcinomas. The
ubiquitin-binding region of b-catenin is also in exon 3. Muta-
tion of this region, leading to lack of b-catenin ubiquitization,
has also been shown to be oncogenic.
Given that germline APC mutations in Turcot syndrome
give rise to an increased incidence of medulloblastoma and
given the rarity of APC mutations in sporadic medulloblas-
toma, sporadic medulloblastomas have been screened for
oncogenic mutations in b-catenin, as these mutations result
in the same phenotype as APC inactivation. Exon 3 of
b-catenin, the location of all GSK-3b phosphorylation sites,
was investigated by direct sequencing in 67 sporadic me-
dulloblastomas [77]. Five tumors were found to have
b-catenin mutations. In three cases, the alteration resulted
in the substitution of a cysteine for a serine at a GSK-3b
phosphorylation site. Sequencing of exon 3 in the constitu-
tional DNA from these patients (available for two of the three
patients) failed to show a mutation, indicating that the
mutation identified is tumor-specific. Two additional muta-
tions were found, both of which altered an amino acid in the
ubiquitin-binding region, also in exon 3. Thus, 5 of 67 (7.5%)
tumors had oncogenic mutations in b-catenin. As ex-
pected, those tumors with b-catenin mutations also had
nuclear localization of b-catenin. Similar results have been
reported recently from another group [69], who reported
that of 46 medulloblastomas, four (8.7%) were found to
have oncogenic mutations in b-catenin. The finding that
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one quarter of medulloblastomas have nuclear localization
of b-catenin, whereas only 7.5% contain oncogenic
b-catenin mutations, suggests that alterations in this path-
way—other than b-catenin mutation that result in in-
creased b-catenin/Tcf transcription—may be occurring
in a subset of medulloblastoma.
Asmentioned above, binding of b-catenin by APC leads to
degradation of b-catenin. At least two other proteins are
involved. In humans, these proteins have been called axin1
and axin2 (Figure 5). The protein products of both of these
genes associate with b-catenin, APC, and GSK-3b. Both
proteins appear to facilitate phosphorylation of b-catenin by
GSK-3b. In fact, in the absence of axin, GSK-3b phosphor-
ylates b-catenin poorly. A role for axin1 in bringing GSK-3b
and b-catenin together by mutual binding has been pro-
posed. Inactivation of axin1 or axin2 would be expected to
increase levels of free b-catenin through decreased degra-
dation and, thus, increase b-catenin/Tcf–mediated tran-
scription. Indeed, axin1 has been shown to be mutated in a
subset of hepatocellular carcinomas [78]. Hepatocellular
carcinoma cell lines with mutated axin1 demonstrated nu-
clear localization of b-catenin. Replacement of axin1 activity
by transfection with wild-type axin1 resulted in apoptosis in
these cell lines.
Medulloblastomas have been examined for axin1 muta-
tions [79,80]. In the first study, of 86 tumors, eight were found
to have mutations in axin1. There were seven deletions that
went from intron to intron and included at least two exons and
one point mutation. In four instances, an LOH analysis
revealed no evidence of loss of the wild-type allele. However,
the second study revealed these large deletions to be a
PCR artifact. The actual frequency of axin1 mutations is
low, with missense mutations found in 2 of 39 tumors
examined. These results suggest that axin1 mutations are
rare in medulloblastoma.
A third genetic alteration found in medulloblastoma is
c-myc or N-myc amplification. Amplification of myc genes
is rare, occurring in only 4% of medulloblastomas. Interest-
ingly, c-myc amplification appears to correlate with the large
cell phenotype, which carries a particularly grim prognosis.
Other Growth Factor Pathways in Medulloblastoma
Gilbertson et al. [81–83] have investigated the expression of
erbB family members in medulloblastoma. They have shown
that erbB2 and erbB4 are frequently expressed together in
medulloblastoma. Interestingly, erbB4, but not erbB2, was
expressed in the developing cerebellum. Expression of
erbB2 and erbB4 was associated with simultaneous expres-
sion of neuregulin1-a, suggesting the possibility of an auto-
crine loop in tumors with expression of all three proteins.
Indeed, erbB2/erbB4 dimerization was identified in tumors.
This group has also shown that novel splice variants of
erbB4 are found frequently in medulloblastoma. Significantly,
coexpression of erbB2 and erbB4 indicated a worse
prognosis and that expression of these receptors with
neuregulin1-a was associated with CSF dissemination at
presentation.
Activation of IGF-1R has also been demonstrated in
medulloblastoma cell lines [84]. Autophosphorylation of this
receptor and induction of c-fos expression in the presence of
exogenous IGF-1 have been shown, indicating a functional
receptor. Tumor growth was inhibited by an anti– IGF-1R
antibody that interferes with ligand binding. Similar results
have been reported by others [85].
Murine Models of Medulloblastoma
In the past, xenografts of established medulloblastoma cell
lines in nude mice have been used as the standard model for
this tumor in translational research. Unfortunately, these
models suffer from a number of problems. First, the two most
commonly used cell lines are not typical of the human tumor.
One of these, TE671 was used for a number of years until
proven to be a sarcoma rather than a medulloblastoma [86].
The second, Daoy, has genetic alterations (such as absence
of wild-type p53 and homozygous deletion of the CDKN2
gene, which encodes the tumor suppressors p16 and p15)
that are more characteristic of other types of brain tumors
than of medulloblastoma [87,88]. This raises the issue of the
use of cell lines to model medulloblastoma. PNETs have
proven difficult to establish in culture. Only a few cell lines
have been well characterized. Thus, it is possible that the
established cell lines are not representative of PNET as a
whole. Established cell lines could represent a subpopulation
of PNET with specific mutations that allow for growth in vitro,
or in vitro passage could select for mutations that occur
during initial passages that allow the tumor to grow in vitro.
Because of the limitations of xenograft models, and in an
attempt to replicate the human tumor, two laboratories have
developed ptch knockout mice [89,90]. Homozygous inacti-
vation of ptch causes embryonic lethality due to CNS system
defects including failure of neural tube closure; overgrowth of
head folds, hindbrain, and spinal cord; and cardiac defects
[89]. Hemizygous ptch mice (ptch +/) have many of the
features of Gorlin syndrome, including skeletal abnormalities,
neural tube closure defects, a generalized overgrowth, and a
predisposition to tumor development. Indeed, about 30% of
these mice develop tumors in the cerebellum that resemble
human medulloblastoma histologically (Figure 2B). As
expected, expression of gli1 is increased in these tumors,
compared to expression in normal cerebellum, suggesting
activation of the SHH signaling pathway in these tumors.
Surprisingly, two independent studies have failed to demon-
strate any alteration in the wild-type allele in the murine
tumors [91,92]. Given the incidence of the tumors and the
retention of the wild-type allele, the possibility of epigenetic
silencing of the wild-type allele or mutation in other genes
must be considered in this model. Epigenetic silencing is
unlikely, as both studies demonstrate expression of wild-type
mRNA in the tumors. However, a recent study has suggested
that the wild-type ptch allele is silenced through methylation
[93]. Unlike the two studies mentioned above, these inves-
tigatorswere unable to identifywild-typeptchmRNA in tumors
from ptch +/ mice. They show that treatment of tumor cell
lines with an inhibitor of methylation results in downregulation
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of the SHH/ptch pathway in tumor cell lines. How to reconcile
this result with the identification of wild-type message in
tumors cells by in situ hybridization is problematic.
The issue of other genes cooperating with hemizygous
inactivation of ptch has been investigated by Wetmore et al.
[94]. When the hemizygous ptch alteration is placed in a
p53-null background, more than 95% of the mice develop
medulloblastoma. In addition, the tumor arises earlier on a
p53-null background when compared to the timing of tumor
development when normal p53 is present. The increase in
tumor development was seen only on a p53-null back-
ground and was not associated with an APC hemizygous
background (Min +/) or a p19/ARF hemizygous inactiva-
tion background. Given that p53 alterations are rarely seen
in sporadic human medulloblastoma, these results suggest
the possibility that the increased genomic instability of the
p53-null background may lead to mutations in genes that
cooperate with the hemizygous ptch alteration in the forma-
tion of these tumors.
Another murine model of medulloblastoma that depends
upon the overactivity of the SHH pathway has been devel-
oped by Weiner et al. [95]. These investigators have injected
the early cerebellar precursors of E13.5 mice in utero with a
SHH-containing retroviral vector, using a sophisticated ultra-
sound guided technique. When examined at P14 or P21, the
injected mice have retained the EGL, suggesting that con-
tinued expression of SHH in the EGL results in persistent
mitosis or prevents differentiation. In addition, the cerebellum
of injected mice contains nodules of mitotically active tissues
that resemble medulloblastoma. When examined at 13
weeks of age, injected mice have larger tumors that are
exerting mass effect on the cerebellum. Interestingly, given
the role of gli1 in the SHH pathway, identical findings were
seen when fetuses of gli1-null mice were injected with the
retrovirus. This result suggests that gli1 is not required for
tumor development in this model. Perhaps another gli family
member is sufficient.
A similar murine model of medulloblastoma has been
developed using the replication-competent ALV splice
(RCAS)/tv-a system [96]. In this model, a mouse line express-
ing the avian retroviral vector receptor, tv-a, under the control
of the nestin promoter was used. Neonatal mice were injected
with an avian RCAS acceptor vector into the cerebellum.
Three of 32 mice (9%) developed medulloblastoma. An addi-
tional 5 of 32 developed multifocal persistence and hyper-
proliferation of the EGL. When the nestin/tv-a mice were
injected with both a SHH/RCAS vector and a c-myc/RCAS
vector, 9 of 39mice (23%) developedmedulloblastoma. These
results suggest that a nestin-expressing cell in the neonatal
cerebellum is able to serve as a precursor to medullo-
blastoma. Whether the cooperation between SHH and c-myc
relates to the human tumor remains to be investigated.
An interesting model of medulloblastoma has been
reported in lig4-null mice. The lig4 gene encodes a protein
that participates in the repair of DNA double-strand breaks
by the nonhomologous end joining (NHEJ) complex. Mice
null for lig4 die in late embryonic development because of
extensive apoptosis of neurons in the CNS [97]. However,
p53-null, lig4-null mice survive [98]. The double-null mice
develop both lymphomas and medulloblastomas [99]. These
investigators attribute the DNA strand breaks to ‘‘genotoxic
stress’’ and suggest that the development of medullo-
blastoma in the double-null mice is related to mutations in
undefined genes caused by improper repair of DNA damage.
Which genes these may be has not been determined.
A second model of medulloblastoma in mice that com-
bines the p53-null state with defective DNA repair has also
been described [100]. In this model, the DNA repair gene
inactivated is poly(ADP-ribose polymerase) (PARP-1), a
DNA strand break–sensing gene that is activated as an
early response to DNA damage. When p53-null, PARP-1–
null mice were investigated, they were found to have a high
frequency of a cerebellar tumor resembling human medullo-
blastoma. The progression of these tumors was associated
with reactivation of expression of Math-1, a transcription
factor expressed in the EGL. Like the preceding model, this
model suggests that disruption of DNA repair in the EGL can
give rise to medulloblastoma. The genes mutated in this
model have also not been identified.
Two other murine models of medulloblastoma that involve
the inactivation of p53 and pRB1 have been developed. In an
attempt to generate astrocytic tumors, Marino et al. [22]
constructed a mouse with conditional knockout of the RB1
gene using the Cre/LoxP system. The Cre recombinase was
placed under control of the GFAP promoter to establish Cre
expression in astrocytes. When the GFAP-Cre mice were
crossed with RbLoxp/LoxP mice, inactivation of Rb in cells that
express GFAP occurs. When these conditions of RB1
knockout mice were combined with a p53-null background,
the resulting mice developed lymphoma, sarcomas, and
tumors of the cerebellum resembling medulloblastoma.
These investigators were able to demonstrate GFAP expres-
sion in the EGL precursors in the cerebellum of normal mice
and inactivation of RB1 in the same cells in the GFAP-Cre,
RbLoxp/LoxP mice. These results suggest that the tumors are
indeed arising from EGL precursors. In addition, alteration of
cell cycle control by RB1 inactivation is implicated in the
development of this tumor in mice.qqq
A different model of medulloblastoma that also involves
inactivation of pRB and p53 has been developed by Krynska
et al. [101]. These investigators constructed a transgenic
mouse line with the early sequences from JC virus that
contain the early promoter and the large T antigen gene.
These mice developed tumors of the cerebellum that resem-
ble medulloblastoma. This model shares functional features
with the model of Marino et al. in that large T antigen binds
and functionally inactivates both p53 and pRb. In addition,
tumors expressing T antigen contained evidence of in-
creased activity of the b-catenin/Tcf transactivator, which
has been implicated in the development of a subset of
human tumors.
Given that human medulloblastomas rarely contain either
p53 or pRB alterations, results from these two models
may not be easily extrapolated to the human condition.
Possibly, these models indicate that EGL precursors are
easily transformed by a number of possible alterations, only
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some of which occur in humans. Alternatively, the key event
in the generation of these tumors may not be the alteration in
control of the cell cycle, but may rather relate to the activation
of events such as b-catenin/Tcf–regulated transcription that
have been seen in the human condition.
In summary, a number of murine models of medulloblas-
toma have been described. Some of these are the result of
genetic alterations that are similar to those defined in human
tumors, whereas others seem unrelated to the human
condition. Hopefully, work with these models will lead to
new insights into human medulloblastoma and to better
therapies directed by the molecular alterations. Additional
models with alterations in b-catenin or other wnt pathway
members have yet to be described.
Summary
A great deal of information about the genetic alterations
leading to the pediatric brain tumor medulloblastoma has
been reported. Subsets of tumors with alterations in genes
important in CNS development have been defined and
murine models based on some of these have been gener-
ated. Nonetheless, the percentage of tumors that have
identified gene alterations is less than 50% of the total.
Clearly, more work is needed to define what alterations are
responsible for uncontrolled cell proliferation in a majority
of these tumors.
Glossary
Cerebellum
A part of the brain involved in control of
coordination and balance. Made up of two
laterally placed hemispheres connected by a
central portion called the vermis
CSF A clear, colorless fluid made by the brain.
Fluid is made in chambers inside the brain
(called ventricles), flows through channels in
the brain to get outside the brain, bathes the
surface of the brain and spinal cord, and is
absorbed into the venous bloodstream
Hydrocephalus
When circulation of CSF is blocked, synthesis
of the fluid continues, leading to accumulation
of the fluid in the chambers in the brain. The
chambers enlarge and exert pressure on the
surrounding brain
Pleomorphic
Having a varied appearance related to cell
size, cell shape, and nuclear size
Synaptophysin
A protein component of the vesicles that
contains neurotransmitters in neurons
GFAP An intermediate filament protein whose gene
expression is restricted to astrocytes, one of
the three main cell types in the brain
SHH An extracellular signaling molecule. The
protein is cleaved into two parts; the active
amino-terminal portion is also cholestero-
lated. Its homolog in Drosophila is hedgehog
PTCH The membrane-bound receptor for SHH. The
protein contains 12 transmembrane domains
and associates in the membrane with v-smo.
The Drosophila homolog is patched
v-smo The effector of SHH signaling. PTCH exerts
inhibition of v-smo activity; this inhibition is
released by SHH binding to PTCH. The
Drosophila homolog is smoothened
gli1 An intracellular effector of SHH signaling.
There are three members of the gli family.
The Drosophila homolog is cubitus interruptus
Neurotrophins
A family of growth and differentiation factors
related to nerve growth factor (NGF) and
including NGF, BDNF, neurotrophin 3 (NT3),
and neurotrophin 4 (NT4)
Neurotrophin receptors
The trk family of tyrosine kinases. TrkA has
the highest affinity for NGF, trkB for BDNF,
and trkC for NT3
PDGFRA
One of two tyrosine kinase receptors for
platelet-derived growth factor (PDGF)
APC The adenomatous polypi coli gene. The
protein product of this gene is involved in
the degradation of phosphorylated b-catenin
b-Catenin
A transcriptional transactivator involved in wnt
signaling
Tcf The T-cell factor family contains four mem-
bers. They provide the DNA-binding specific-
ity for the b-catenin/Tcf transactivator
axin1 A gene whose protein product is part of the
APC complex that degrades phosphorylated
b-catenin
EGFR The membrane-associated tyrosine kinase
receptor for epidermal growth factor and
transforming growth factor-a
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IGF-1R The membrane-associated tyrosine kinase
receptor for insulin-like growth factor 1
Xenograft
Growth of tissue from one species in a
different species
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